"HIV-1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte.
| Descriptor ID |
D015497
|
| MeSH Number(s) |
B04.820.650.589.650.350.400
|
| Concept/Terms |
HIV-1- HIV-1
- Human immunodeficiency virus 1
- HIV-I
- Immunodeficiency Virus Type 1, Human
- Human Immunodeficiency Virus Type 1
|
Below are MeSH descriptors whose meaning is more general than "HIV-1".
Below are MeSH descriptors whose meaning is more specific than "HIV-1".
This graph shows the total number of publications written about "HIV-1" by people in this website by year, and whether "HIV-1" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 1 | 2 |
| 1996 | 1 | 0 | 1 |
| 1997 | 2 | 1 | 3 |
| 1998 | 9 | 1 | 10 |
| 1999 | 6 | 0 | 6 |
| 2000 | 3 | 2 | 5 |
| 2001 | 2 | 0 | 2 |
| 2002 | 1 | 1 | 2 |
| 2003 | 7 | 0 | 7 |
| 2004 | 6 | 0 | 6 |
| 2005 | 2 | 0 | 2 |
| 2006 | 4 | 1 | 5 |
| 2007 | 4 | 2 | 6 |
| 2008 | 2 | 1 | 3 |
| 2009 | 3 | 0 | 3 |
| 2010 | 4 | 2 | 6 |
| 2011 | 5 | 2 | 7 |
| 2012 | 5 | 3 | 8 |
| 2013 | 6 | 3 | 9 |
| 2014 | 6 | 4 | 10 |
| 2015 | 8 | 3 | 11 |
| 2016 | 5 | 2 | 7 |
| 2017 | 4 | 1 | 5 |
| 2018 | 6 | 5 | 11 |
| 2019 | 2 | 2 | 4 |
| 2020 | 1 | 1 | 2 |
| 2021 | 3 | 1 | 4 |
| 2022 | 5 | 0 | 5 |
| 2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "HIV-1" by people in Profiles.
-
The structural basis for HIV-1 Vif antagonism of human APOBEC3G. Nature. 2023 Mar; 615(7953):728-733.
-
A click chemistry amplified nanopore assay for ultrasensitive quantification of HIV-1 p24 antigen in clinical samples. Nat Commun. 2022 Nov 11; 13(1):6852.
-
Mutations of tyrosine 467 in the human norepinephrine transporter attenuate HIV-1 Tat-induced inhibition of dopamine transport while retaining physiological function. PLoS One. 2022; 17(9):e0275182.
-
Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose Rifapentine. Clin Infect Dis. 2022 09 10; 75(4):560-566.
-
Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial. Nat Med. 2022 05; 28(5):1022-1030.
-
Conformation of HIV-1 Envelope Governs Rhesus CD4 Usage and Simian-Human Immunodeficiency Virus Replication. mBio. 2022 02 22; 13(1):e0275221.
-
Cerebrospinal Fluid and Plasma Lipopolysaccharide Levels in Human Immunodeficiency Virus Type 1 Infection and Associations With Inflammation, Blood-Brain Barrier Permeability, and Neuronal Injury. J Infect Dis. 2021 05 20; 223(9):1612-1620.
-
Identification of recombinant Fabs for structural and functional characterization of HIV-host factor complexes. PLoS One. 2021; 16(5):e0250318.
-
Sec24C is an HIV-1 host dependency factor crucial for virus replication. Nat Microbiol. 2021 04; 6(4):435-444.
-
Mutations of Human DopamineTransporter at Tyrosine88, Aspartic Acid206, and Histidine547 Influence Basal and HIV-1 Tat-inhibited Dopamine Transport. J Neuroimmune Pharmacol. 2021 12; 16(4):854-869.